News

Edward Lanphier, president and CEO of Sangamo, said: “We enter 2010 with a strong balance sheet and a robust clinical pipeline. With the initiation of these two new

The primary objective of the study is to investigate whether treatment with A0001 has a discernible impact on various functional, biochemical and subject/clinician-rated scales relevant in the treatment

In the alliance, Galapagos will apply its target discovery platform to discover novel COPD targets. Galapagos will be responsible for the discovery and development of new small molecule

In the open-label, single-arm, Simon-design two-stage Phase II study entitled ‘Saphire’, Resminostat will be given orally at a dose of 600mg daily for five consecutive days, followed by

The company claims that patients who attempted intercourse within 15 minutes of dosing were successful 67%, 69% and 72% of the time on 50, 100 and 200mg of

The company said that the technology is to be housed in Catalent’s Research Triangle Park, North Carolina facility, provides a flexible platform to reliably support all clinical manufacture

Stig Pedersen, executive vice president of commercial operations at Lundbeck, said: “The reimbursement of Azilect is of great importance to the many patients in France suffering from parkinson’s

The company claims that Sidekick works alongside any Octet instrument and enables offline, simultaneous and uniform sample loading on all 96 biosensors on a biosensor tray. This increases

Armodafinil tablets are the generic version of Nuvigil tablets, which are used to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypnea syndrome, narcolepsy and